Back to Authors

Subías, Pilar Escribano

https://orcid.org/0000-0002-6640-4839

A5072002848 | I4210101691

Mayo Clinic

Hospital Universitario 12 De Octubre

Citations 4

Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804612

Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)

A14. BUILDING LEGO(LAND): LESSONS LEARNED FROM LARGE SCALE CLINICAL TRIALS IN PAH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1011-A1011

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1011

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial

D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6726-A6726

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6726

Pulmonary Arterial Hypertension: Epidemiology and Registries

Advances in Pulmonary Hypertension | February 26, 2019 | Volume: 13 | Issue: 1 | Pages: 21-26

10.21693/1933-088x-13.1.21

Registries of pulmonary arterial hypertension (PAH) are important means by which to characterize the presentation and outcome of patients and to provide a basis for predicting the course of the disease. This article summarizes the published conclusions of the World Symposium of Pulmonary Hypertension task force that addressed registries and epidemiology of PAH.